Truebinding Incis A Clinical Stage Biotherapeutic Company Based In San Mateocaliforniafounded In 2015The Company Specializes In Monoclonal Antibody Therapeutics Aimed At Treating Neurodegenerative Diseasesmetabolic Disordersstrokeoncologyand Other Conditions With Significant Unmet Medical Needstruebinding Has Raised A Total Of $229 06 Million In Fundingincluding A Recent $57 71 Million Round Truebinding Offers Contract Development And Manufacturing Services For Biopharmaceutical Clientsutilizing Its Proprietary Platform To Enhance Antibody Productionthis Service Allows For The Rapid Development Of High Quality Monoclonal Antibodieshelping Partners Reduce Time To Market And Coststhe Company Is Currently Developing Tb006A Monoclonal Antibody For Alzheimerae S Diseasewhich Has Shown Positive Results In Clinical Trialsadditionallytruebinding Provides An Expanded Access Program For Alzheimerae S Patients Who Have Exhausted Other Treatment Optionsthe Company Is Committed To Advancing Biopharmaceutical Innovation Through Strategic Partnerships And Internal Research And Development
